Marker Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $3.9M-40.1% YoYTTM through 31 Mar 2026
Net Income -$8.7MTTM through 30 Jun 2026
Free Cash Flow -$9.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -178.0% |
| Operating Margin | -363.5% |
| Net Margin | -220.5% |
Returns
-72.4%ROE
-63.8%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio8.39x
Net Debt-$16.1Mnet cash position
Cash & Equivalents$11.3M
Quality Metrics
Altman Z-Score-40.39
Piotroski F-Score2 / 9
FCF Margin-247.0%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $3.5M
Diluted EPS-$0.38TTMFY2025: $-0.79
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Grant Income | $3.5M | -46.2% | View detailsMarker Therapeutics continues to rely on non-dilutive grant funding to support its clinical programs, including the MT-601 and MT-401-OTS programs. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.